Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611674 · ClinicalTrials.gov registry record
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 138
- Enrollment target
NCT02611674 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 138 participants.
The verdict
NCT02611674 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 138 participants
- Enrollment target
Study Summary
The primary objectives of the study are to estimate and rank-order the longitudinal standardized mean changes over 6 months and over 12 months, for a set of outcome measures administered to participants with amyotrophic lateral sclerosis (ALS), in order to identify measures that are more sensitive to disease progression than Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R). The secondary objectives of this study are: To evaluate the test-retest reproducibility of each outcome measure; To determine correlations between 6 and 12-month changes in all exploratory measures with 18 and 24-month changes in ALSFRS-R and survival; To assess correlations between/among the various measures; To obtain biological samples in order to identify molecular correlates to the clinical measures and to further characterize previously identified and novel molecular biomarkers of disease progression for incorporation into future clinical studies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2016-01-06 |
| Est. Completion | 2019-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02611674
The ClinicalTrials.gov registry entry for NCT02611674 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02611674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02611674 about?
NCT02611674 is a clinical study titled "Methodology Study of Novel Outcome Measures to Assess Progression of ALS". The primary objectives of the study are to estimate and rank-order the longitudinal standardized mean changes over 6 months and over 12 months, for a set of outcome measures administered to participants with amyotrophic lateral sclerosis (ALS), in order to identify measures that are more sensitive t...
What is the current status of trial NCT02611674?
This trial is currently completed. The enrollment target is 138 participants. The study started on 2016-01-06. Estimated completion is 2019-08-01.
Who is sponsoring clinical trial NCT02611674?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.